Impact of respiratory infectious epidemics on STEMI incidence and care

Autor: S. Macherey, M. M. Meertens, C. Adler, S. Braumann, S. Heyne, T. Tichelbäcker, F. S. Nießen, H. Christ, I. Ahrens, F. M. Baer, F. Eberhardt, M. Horlitz, A. Meissner, J. M. Sinning, S. Baldus, S. Lee

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)

Abstract The effect of respiratory infectious diseases on STEMI incidence, but also STEMI care is not well understood. The Influenza 2017/2018 epidemic and the COVID-19 pandemic were chosen as observational periods to investigate the effect of respir

Externí odkaz: https://doaj.org/article/ffc9d503b5354414a3ffb7a555fd7af2

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.

Autor: Giraud EL; Department of Pharmacy, Radboud University Medical Center, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: https://twitter.com/ElineGirau45556., Westerdijk K; Department of Medical Oncology, Radboud University Medical Center, Radboud University Medical Center, Nijmegen, The Netherlands., van der Kleij MBA; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Meertens M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bleckman RF; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Rieborn A; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands., Mohammadi M; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Roets E; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands., Reyners AKL; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Touw DJ; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Keizer-Heldens P; Department of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands., Oosten AW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., van der Graaf WTA; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Erp NP; Department of Pharmacy, Radboud University Medical Center, Radboud University Medical Center, Nijmegen, The Netherlands., Desar IME; Department of Medical Oncology, Radboud University Medical Center, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Ingrid.desar@radboudumc.nl.

Publikováno v: ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103477. Date of Electronic Publication: 2024 Jun 03.

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

Autor: van Berge Henegouwen JM; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van der Wijngaart H; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Zeverijn LJ; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoes LR; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meertens M; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Labots M; Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands. A.J.Gelderblom@lumc.nl.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jul; Vol. 90 (1), pp. 97-104. Date of Electronic Publication: 2022 May 22.